Intercept Pharmaceuticals Inc (NASDAQ:ICPT) 2018 Q2 Sentiment Reported At 1.27

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Corporate Logo

Intercept Pharmaceuticals Inc’s Sentiment

“Big money sentiment for Intercept Pharmaceuticals Inc (NASDAQ:ICPT) in Q2 2018 increased to 1.27, SEC.gov filings reveal. That’s up 0.12, from 2018Q1’s 1.15. 70 investment professionals started new or increased stock positions, while 55 sold and reduced their holdings in Intercept Pharmaceuticals Inc so the sentiment has improved. Funds own 19.65 million shares, up from 18.85 million shares in 2018Q1. Funds holding Intercept Pharmaceuticals Inc in top 10 changed to 2 from 1 for an increase of 1. In total 15 funds closed positions, 40 reduced and 45 increased. Also 25 funds bought new Intercept Pharmaceuticals Inc stakes.

Most Intercept Pharmaceuticals Inc Shareholders

As of Q2 2018 Sarissa Capital Management Lp has 10.69% invested in Intercept Pharmaceuticals Inc. Intercept Pharmaceuticals Inc’s shareholder Elk Creek Partners Llc owns 386,397 shares as of Q2 2018. Bb Biotech Ag reported 545,719 shares. The Connecticut-based fund Altrinsic Global Advisors Llc have invested about 1.27% of the active investment manager’s stock portfolio in Intercept Pharmaceuticals Inc. The New York-based fund Opus Point Partners Management Llc holds 3,998 shares or 0.73% of their long stock exposure.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.The firm is worth $3.23 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).Currently it has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Ticker’s shares touched $108.81 during the last trading session after 4.38% change.Intercept Pharmaceuticals, Inc. has volume of 315,653 shares. Since November 10, 2017 ICPT has risen 19.09% and is uptrending. ICPT outperformed the S&P500 by 3.47%.

Raymond James Assoc holds 0.01% or 78,476 shs in its capital. Great West Life Assurance Can reported 1,989 shs. Sandy Spring Fincl Bank holds 200 shs or 0% of its capital. Deutsche National Bank Ag holds 351,247 shs. Bb Biotech Ag holds 1.32% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) or 545,719 shs. Goldman Sachs Gp reported 190,384 shs. Alliancebernstein L P holds 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) or 102,570 shs. Fifth Third National Bank & Trust reported 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). 3,339 are held by Automobile Association. Wellington Group Limited Liability Partnership holds 5,816 shs or 0% of its capital. 383,166 are held by Altrinsic Global Advisors Limited Liability. 219,360 were accumulated by Geode Cap Management. Opus Point Ltd invested in 3,998 shs or 0.73% of the stock. Morgan Stanley stated it has 81,996 shs. Schwab Charles Invest Management accumulated 110,805 shs.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

In total 7 analysts cover Intercept Pharmaceuticals (NASDAQ:ICPT). “Buy” rating has 5, “Sell” are 0, while 2 are “Hold”. (NASDAQ:ICPT) has 71% bullish analysts. 8 are the (NASDAQ:ICPT)’s ratings reports on 10 Nov 2018 according to StockzIntelligence Inc. On Monday, August 6 the firm has “Outperform” rating by Wedbush given. On Monday, August 6 Goldman Sachs upgraded Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to “Buy” rating. On Wednesday, August 15 the stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Sector Perform” rating by RBC Capital Markets. On Monday, October 1 the stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Overweight” rating given by Cantor Fitzgerald. In Tuesday, October 2 report Raymond James downgraded the stock to “Outperform” rating. On Friday, August 3 the company was downgraded by Laidlaw.

For more Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news announced briefly go to: Seekingalpha.com, Nasdaq.com, Fool.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Key events next week – healthcare” announced on November 02, 2018, “Report: Developing Opportunities within Vitamin Shoppe, Intercept Pharmaceuticals, Viasat, Team, Valvoline, and …” on October 24, 2018, “Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock” with a publish date: October 16, 2018, “Intercept Pharmaceuticals (ICPT) Q3 2018 Results – Earnings Call Transcript” and the last “Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018” with publication date: November 05, 2018.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.